|
|
Vaccine Detail
|
NY-ESO-1/GLA-SE Vaccine ID-G305AmN |
| Vaccine Information |
- Vaccine Name: NY-ESO-1/GLA-SE Vaccine ID-G305AmN
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007026
- Type: Multipeptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: NY-ESO-1
- CTAG1B
gene engineering:
- TLR4
gene engineering:
- Preparation: G305 is a recombinant NY-ESO-1 protein vaccine mixed with glucopyranosyl lipid A (GLA), a synthetic TLR4 agonist adjuvant, in a stable emulsion (Mahipal et al., 2019).
- Description: This is for Melanoma, Ovarian Cancer, Sarcoma, Non-small Cell Lung Cancer and Breast Cancer(NCT02015416).A cancer vaccine composed of a recombinant form of the tumor antigen NY-ESO-1 and glucopyranosyl lipid adjuvant (GLA)-stable emulsion (GLA-SE), with potential antineoplastic and immunomodulating activities. Upon intramuscular injection, the adjuvant portion of the NY-ESO-1/GLA-SE vaccine ID-G30 binds to toll-like receptor subtype 4 (TLR-4) expressed on dendritic cells (DCs), monocytes, macrophages and B cells. The activated DCs present the NY-ESO-1 antigen to Th1 CD4 T-lymphocytes. This leads to the induction of cytotoxic T lymphocytes (CTLs) and the killing of NY-ESO-1-expressing tumor cells. This vaccine also induces specific antibody responses and increases the production of inflammatory cytokines(Mahipal et al., 2019; NCIT_C113432).
|
| Host Response |
|
|
| References |
Mahipal et al., 2019: Mahipal A, Ejadi S, Gnjatic S, Kim-Schulze S, Lu H, Ter Meulen JH, Kenney R, Odunsi K. First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1. Cancer immunology, immunotherapy : CII. 2019; 68(7); 1211-1222. [PubMed: 31069460].
NCIT_C113432: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C113432]
NCT02015416: [https://clinicaltrials.gov/ct2/show/NCT02015416]
|
|
